Drug updated on 9/4/2024
Dosage Form | Tablet (oral; 500 mg, 1000 mg) |
Drug Class | Iron chelators |
Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- For the treatment of transfusional iron overload in adult and pediatric patients 8 years of age and older with thalassemia syndromes, sickle cell disease or other anemias.
Latest News
Summary
- Ferriprox (deferiprone) is indicated for the treatment of transfusional iron overload in adult and pediatric patients 8 years of age and older with thalassemia syndromes, sickle cell disease, or other anemias.
- This summary is based on the review of three systematic review(s)/meta-analysis(es). [1-3]
- Deferasirox and deferiprone demonstrate higher compliance rates (90% to 100% and 87.2% to 92.2%, respectively) compared to desferioxamine (48.84% to 85.1%).
- Poor compliance is associated with increased risks of liver disease (57.14% of studies), cardiac disease (75% of studies), endocrinologic morbidity (90% of studies), and lower HRQoL (66.67% of studies).
- No significant difference was observed between DFX and DFP in MRI T2* (WMD: -0.92; 95% CI [-3.35, 1.52]; p = 0.46) and serum ferritin levels at 6 months (WMD: 97.31; 95% CI [-236.16, 430.77]; p = 0.57) and 12 months (WMD: 46.99; 95% CI [-191.42, 285.40]; p = 0.70).
- Medication adherence comparisons between deferiprone, desferioxamine, and deferasirox showed uncertain effects. The combination of deferiprone and deferasirox demonstrated a possible benefit compared to deferiprone and desferioxamine (RR 0.84; 95% CI 0.72 to 0.99).
- Serious adverse events (SAEs) in comparisons between deferiprone, deferasirox, and desferioxamine were reported as uncertain, with one trial showing a relative risk (RR) of 1.43 (95% CI 0.83 to 2.46) for deferiprone vs. desferioxamine. Possible benefits were suggested in chelation-related adverse events for Deferasirox FCT vs. DT.
- All-cause mortality was uncertain across the drug comparisons, with a RR of 0.47 (95% CI 0.18 to 1.21) for deferiprone vs. desferioxamine, and no deaths reported in the trial period for combination therapies.
- The key findings for specific population types include higher compliance rates with deferiprone and deferasirox in thalassemia patients, no significant differences in efficacy between DFX and DFP in pediatric patients with hemoglobin disorders, and uncertain effects on medication adherence and quality of life across different drug comparisons for individuals with sickle cell disease and thalassemia.
Product Monograph / Prescribing Information
Document Title | Year | Source |
---|---|---|
Ferriprox (deferiprone) Prescribing Information. | 2021 | Chiesi USA, Inc., Cary, NC |
Systematic Reviews / Meta-Analyses
Document Title | Year | Source |
---|---|---|
The impact of chelation compliance in health outcome and health related quality of life in thalassaemia patients: A systematic review. | 2024 | Health and Quality of Life Outcomes |
No difference in myocardial iron concentration and serum ferritin with deferasirox and deferiprone in pediatric patients with hemoglobinopathies: A systematic review and meta-analysis. | 2023 | Transfusion Clinique et Biologique |
Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia. | 2023 | The Cochrane Database of Systematic |
Clinical Practice Guidelines
Document Title | Year | Source |
---|---|---|
Guidelines for the monitoring and management of iron overload in patients with haemoglobinopathies and rare anaemias. | 2023 | British Journal of Haematology |
2021 Thalassaemia International Federation Guidelines for the Management of Transfusion-dependent Thalassemia. | 2021 | Hemasphere |
Guidelines for the management of transfusion dependent thalassaemia. | 2021 | Thalassaemia International Federation |